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ABSTRACT
Backround: Sleep disorders are prevalent in patients with advanced cancer. Their
impact on clinical outcomes is not well understood.
Methods: A post-hoc analysis was conducted in 361 patients previously untreated for
metastatic disease with metastatic colorectal cancer completing twice the EORTC
QLQ-C30 questionnaire within a randomized international phase III trial. The study
assessed the effect on overall survival (OS) of subjective sleep complaint, used as a
normal or a time-dependent covariate (TDC), using a multivariate Cox proportional
hazard model. Prognostic analysis was conducted on the whole study population and
separately in each treatment arm (conventional FOLFOX2, or chronomodulated
chronoFLO4).
Results: Sleep problems were reported by 202 patients (56%) at baseline and by 188
(52%) on treatment. Sleep problems at baseline were independently associated with a
higher risk of earlier death (HR: 1.36; p=0.011), progression (HR: 1.43; p=0.002) and
poor treatment response (RR: 0.58; p=0.016). TDC analysis confirmed the
independent prognostic effect of sleep problems on OS (HR: 1.37; p=0.008), while on
treatment this effect was only observed using univariate analysis. The negative
prognostic value of sleep problems on OS, at baseline, on treatment and as a TDC,
was greatest on chronoFLO4 compared to FOLFOX2.
Conclusions: Subjective sleep problems are associated with poor clinical outcomes in
metastatic colorectal cancer patients and affect effectiveness of chronomodulated
chemotherapy. There is a need for a well-tuned circadian timing system in order to
increase chronomodulated chemotherapy activity. Prospective studies are needed for
determining the impact of therapeutic approaches on sleep disorders upon quality of
life and survival of cancer patients.
INTRODUCTION
Sleep problems are prevalent in cancer patients and survivors, with nearly two-thirds
of patients reporting them 1-4. However, relatively little is known about sleep
disorders in colorectal cancer patients. In a study of 157 adults with colon or rectal
cancer, sleep problems were reported by 35% of patients, and higher levels of sleep
problems predicted for more fatigue, together with more depression and poorer
performance status 5. In another small study involving 21 patients with colorectal
cancer undergoing adjuvant chemotherapy, clinically significant sleep disturbance
was observed 6. Berger et al. also noted substantial evidence of circadian disruption in
that sample, suggesting that patients diagnosed with these types of cancer experience
lack of distinction between nighttime and daytime in their activities 6. This
phenomenon was previously described in patients with advanced cancers where
substantial amount of time spent asleep during the day and awake during the night
effectively blurs the line between day and nighttime 7-9. The observed association
between altered rest-activity rhythm and subjectively-reported sleep problems in two
independent cohorts of patients with metastatic colorectal cancer 10, 11 further
supported the hypothesis that disruption of circadian rhythms in cancer patients plays
a role in the occurrence of sleep problems. .
Evidence from several epidemiological studies suggests that chronic circadian
disruption is carcinogenic and associated with increased risk of many cancers,
including colorectal cancer 12, 13. Sleep disorders have also been reported to be
associated with numerous adverse psychiatric and health outcomes, including
neurocognitive, metabolic, endocrine, and immune effects, increased fatigue,
decreased physical activity, drowsiness, anxiety, depression, and increased perception
of pain14-16. These data point to circadian disruption as a potential mechanism for
sleep problems and the associated health risks.
Despite this scientific evidence and the common knowledge of adverse health
associated with disturbed sleep, data on large populations of cancer patients are
lacking with regard to the effects of sleep problems on clinical outcomes.
Nonetheless, other patient-reported symptoms have been more extensively studied
and their importance as independent prognostic factors in various cancers, including
advanced colorectal cancer, has been confirmed 1, 17-22.
We examined the prognostic role of subjective sleep complaints before and during
chemotherapy in patients diagnosed with metastatic colorectal cancer using data from
a randomized controlled trial conducted by the European Organisation for Research
and Treatment of Cancer (EORTC) Chronotherapy Group.
PATIENTS and METHODS
Study Objective and Design
This clinical trial enrolled 564 patients previously untreated for metastatic disease
from 36 centers in 10 countries between October 1998 and February 2002; 282
patients were randomly assigned to one of the following treatment arms: FOLFOX2
or chronoFLO4 23 (Figure 1). Both regimens combined oxaliplatin, 5-fluorouracil, and
leucovorin, administered with either a conventional, non-time stipulated 2-day
delivery (FOLFOX2), or with a chronomodulated, circadian-based infusion for 4 days
(chronoFLO4). The description of these schedules, the patient inclusion and exclusion
criteria, and the report of overall outcomes of the trial have been detailed elsewhere
23. The study, approved by the EORTC protocol review committee and the ethics
committee of each participating center, was conducted in compliance with the
Helsinki declaration. All patients provided written informed consent.
Sleep Assessment
Patients’ subjective sleep was measured using the corresponding scale of a
multidimensional questionnaire of HRQoL, the EORTC Quality of Life Questionnaire
C30 (QLQ-C30), version 2.0 24. Assessments were performed at baseline (before
chemotherapy start, but after a variable amount of time since initial cancer diagnosis
and staging workup) and during protocol chemotherapy (every 4th cycle of
chemotherapy, about 2 months apart). The sleep score from EORTC QLQ-C30 was
calculated using the recommended EORTC procedures 24 and involved the
transformation of raw scores of increased severity into a linear scale ranging from 0 to
100. In particular, the EORTC QLQ-C30 questionnaire involves one straightforward
question: “[During the past week] Have you had trouble sleeping?” We considered
that patients had no subjective sleep complaints if they answered “not at all”
(corresponding to 0 on the scale). The other values of the scale (i.e., 33.3, 66.7 or 100,
corresponding to “a little”, “quite a bit” and “very much”, respectively) were
considered a subjective report of sleep problems.
Statistical Analysis
The primary endpoint of this study was the association between subjective sleep
complaints and overall survival (OS). We explored this association using sleep scores
at baseline, while on treatment, and as time-dependent covariates (TDC). In each
case, OS was measured from the date of completion of the corresponding
questionnaire to the date of death (due to any cause). Patients still alive at the time of
database locking were censored at the last date known to be alive. Similarly, time to
progression (TTP) was calculated from the date of questionnaire completion until the
date of disease progression or death, whichever occurred first.
Survival curves and probabilities were estimated using the Kaplan-Meier technique,
and differences between survival curves were assessed using the log-rank test. The
Cox proportional hazards regression model was used for both univariate and
multivariate analyses of survival. For the prognostic analysis, the subjective sleep
complaint was used either as a simple variable or as a time-dependent covariate. A
multivariate prognostic model was then built, forcedly entering other possible
prognostic factors. The added adjusting factors included: randomized treatment, age,
sex, site of primary tumor, resection of primary tumor, Duke’s stage at diagnosis,
prior adjuvant chemotherapy, World Health Organization (WHO) performance status
(PS) at baseline, number of metastatic sites, body mass index (BMI) at baseline,
anemia, leukocytosis, and elevated alkaline phosphatases or lactate dehydrogenase
(LDH) 25. For survival analysis using sleep data during treatment, PS and BMI at day
1 of the corresponding chemotherapy cycle of questionnaire completion were used
instead of baseline values. In this latter model, the number of chemotherapy cycles
received was also entered in the final Cox model. All analyses were performed in the
whole study population and subsequently, in each treatment arm separately.
Moreover, exploratory subgroup analyses were performed to observe differences in
the prognostic significance of subjective sleep complaints on OS.
The best objective tumor response (OR) was assessed using WHO criteria. Univariate
and multivariate binary logistic regression was used to assess the predictive role of
baseline sleep complaints on response rate.
Baseline clinical and demographic factors associated with subjective sleep complaints
were explored using 2-sided Chi-square (for categorical variables) or Wilcoxon t-test
(for quantitative variables). The level of statistical significance was set at p<0.05. All
analyses were performed using PASW 16 software (SPSS Inc., USA).
RESULTS
Demographics and biomedical characteristics of study patients
Out of the 564 enrolled patients, 361 patients (64%) had available sleep assessment
both at baseline and at least one during treatment. . Demographics and biomedical
characteristics in the current study population (n=361), summarized in Table 1, were
comparable to those of the whole population of the EORTC 05963 trial (data not
shown) 23.
The interval between baseline sleep assessment and the last HRQoL assessment while
on treatment is shown in Figure 1.
Prevalence of subjective sleep problems at baseline and on treatment
Prevalence of sleep problems is shown in Figure 1. There were no differences
between treatment arms concerning sleep problems reported at either baseline or
during treatment.
Overall, 131 patients (36.3%) reported sleep problems at both assessments (baseline
and while receiving treatment); no mention of sleep problems was recounted by 102
patients (28.3%) at both assessments. New onset sleep problems were reported by 57
patients (15.8%), and 71 patients (19.7%) experienced sleep remission while
receiving chemotherapy. These figures were comparable in patients on FOLFOX2
and on chronoFLO4 (p=0.74; data not shown).
Clinical and demographic factors associated with subjective sleep problems
Out of the entire baseline clinical factors screened, only female sex (p=0.023) and
poor PS (p=0.002) were significantly associated with baseline sleep problems (Table
1). Thus, sleep problems were more prevalent in females than in males, and in
patients with poorer PS as compared to those with better PS=0, both at baseline and
on treatment (p=0.018 and p=0.01, respectively).
Relationships between patient-reported sleep problems and clinical outcomes
The presence of subjective sleep complaints at baseline was associated with a 39%
higher risk of earlier death (95% confidence interval [CI]: 11% to 74%; p=0.0034), a
44% higher risk of earlier disease progression (16% to 78%; p=0.0009), and a 42%
lower chance of obtaining an objective response (complete or partial) (11% to 62%;
p=0.011) (Figure 2). Thus, median overall survival in patients with sleep complaints
at baseline was 19.1 months (95% CI: 16.6 to 21.7 months) as compared to 21.7
months (18.6 to 24.8 months) in patients not reporting sleep complaints at baseline.
Similarly, median time to progression was 8.3 (7.5 – 9.0) and 10.0 months (8.9 –
11.1), respectively, in patients with and without sleep problems at baseline. Finally,
objective response rate was 45.1% (95% CI: 38.3 – 51.9%) among patients with sleep
problems at baseline compared to 58.5% (50.7 – 65.9%) in patients without sleep
problems at baseline (Figure 2).
Persisting or newly appeared sleep complaints during treatment were significantly
associated with shorter survival. In patients with sleep problems, median overall
survival was 14.1 months (12.6 – 15.5), compared to 15.8 months (13.2 – 18.4) in
patients without sleep problems (data not shown; HR: 1.27; 95% CI: 1.02 to 1.58;
p=0.036). Moreover, when subjective sleep complaints were considered as time-
dependent covariate, their presence predicted significantly shorter overall survival
(HR: 1.30; 95% CI: 1.05 to 1.63; p=0.019).
Following adjustment for other known prognostic factors, baseline sleep problems
remained independently and significantly associated with shorter overall survival,
with an estimated 36% (95% CI: 7% – 72%) increased risk of an earlier death
(p=0.011) (Table 2). The final model included baseline PS, number of metastatic
sites, and elevated LDH values (Table 2). Similarly, baseline sleep problems
remained in the multivariate models, independently predicting both shorter time to
progression (HR: 1.43; 95% CI: 1.13-1.79; p=0.002) and lower objective response
rate (RR: 0.58; 95%CI: 0.37-0.90; p=0.016) (data not shown).
The multivariate model, with sleep problems considered as time-dependent covariate,
confirmed the independent prognostic value of patient-reported altered sleep on
overall survival, with an estimated increased risk roughly unchanged following
adjustment for other possible prognostic factors (HR: 1.37; 95% CI: 1.08 to 1.72;
p=0.008) (Table 2.). The other variables in the final models were the same as in the
previous one (i.e., baseline PS, number of metastatic sites, and LDH) (Table 2).
Conversely, the presence of sleep problems at the last available assessment while on
treatment protocol was not associated with an independent and significantly higher
risk of earlier death (p=0.234). The main prognostic factor was PS at the date of the
last questionnaire completion, along with the number of metastatic sites and LDH
(Table 2).
Overall, exploratory subgroup analyses showed consistently increased risk for an
earlier death in all subgroups tested associated with subjective sleep complaints,
whether used as a simple variable or as a time-dependent covariate (Figure 3).
Differences of survival prognostic models according to treatment arm
Patients with subjective report of sleep problems at baseline displayed significantly
shorter survival, regardless of the treatment schedule that they subsequently received.
Indeed, on FOLFOX2, the median overall survival was 17.7 months (15.8 – 19.5) in
patients reporting sleep problems and 22.6 months (15.9 – 29.3) in patients without
sleep problems. Respective corresponding median overall survival values on
chronoFLO4 were 20.9 months (17.8 – 24.0) and 21.3 months (18.5 – 24.1) (Figure
4). This translated into a highly similar hazard ratio for earlier death (HR=1.41; 95%
CI: 1.04 to 1.93; p=0.029 on FOLFOX2; HR=1.40; 95% CI: 1.02 to 1.93; p=0.04 on
chronoFLO4, respectively). In multivariate analyses, baseline subjective sleep
problems were associated with a significant shorter survival only in patients receiving
chronoFLO4 (p=0.012) (Table 3). In patients receiving FOLFOX2, the survival
difference was approaching statistical significance (p=0.056) (Table 3).
Subjective sleep problems observed at the last valid assessment while on treatment,
were significantly associated with a shorter survival in patients on chronoFLO4
(p=0.009), and not in those treated with FOLFOX2 (p=0.75) (Figure 4; Table 3).
Thus, median overall survival was similar in patients on FOLFOX2, regardless of the
occurrence (13.6 months; 95% CI: 11.7 – 15.6) or not (15.0 months; 11.6 – 18.3) of
sleep problems while on treatment (p=0.75). Meanwhile, overall survival was
significantly longer in patients without sleep problems (16.7 months; 11.9 – 21.5) as
compared to those complaining of having sleep problems (14.5 months; 11.9 – 17.1)
while receiving chronoFLO4 (p=0.009) (Figure 4). However, on multivariate analysis,
this survival difference did not reach statistical significance (p=0.088) (Table 3).
This difference between treatment regimens and the effect of subjective sleep
problems on overall survival while on treatment was confirmed by time-dependent
covariate analysis, showing a significant association between sleep problems with
shorter overall survival on chronoFLO4 (p=0.006), but not on FOLFOX2 (p=0.54)
(Table 3). In patients treated with chronoFLO4, subjective sleep problems, treated as
time-dependent covariate, independently predicted earlier death, even after adjusting
for other possible prognostic factors (p=0.001) (Table 3).
DISCUSSION
In this study, we showed for the first time that reported good sleep, as measured using
a single subjective questionnaire item, was associated with better clinical outcomes in
patients with metastatic colorectal cancer. We found that 44% of patients who
reported no sleep complaints before chemotherapy treatment (but after diagnosis of
metastatic disease) had a median 2-month increase in overall survival and time to
progression. In addition, these patients had an objective response rate about 13.5%
higher than patients complaining of sleep problems. These positive prognostic effects
of good sleep remained significant even after adjusting for other known prognostic
factors or subgroups. These results further emphasize the clinical relevance of poor
sleep in cancer patients, which has previously been associated with fatigue, mood
disorders, poor functioning, and worse quality of life 14, 15. Sleep problems, however,
remain an overlooked issue in cancer patients, despite the known negative effects of
poor sleep quality and quantity in cancer-free populations, where they represent a
relevant social and health issue 26-28.
This study did not examine the potential mechanism of action behind sleep and
survival. Sleep-wake cycles and circadian rhythms, especially that of rest and activity,
are closely linked 1, 29. An alteration of the circadian rest-activity rhythm has been
shown to be an independent negative prognostic factor in survival in three separate
studies involving patients with advanced colorectal cancer 10, 11, 30, 31. These studies
have also confirmed the correlation between subjective sleep complaints, (measured
with the single item of the EORTC questionnaire), and a clinically relevant circadian
actigraphy parameter, the dichotomy index I<O 10, 11. As such, the current findings are
in agreement with the hypothesis that altered sleep (and circadian function), either
before the start of treatment or during chemotherapy are associated with poorer
outcomes in cancer patients 32, and in good agreement with experimental evidence in
laboratory animals 33. Furthermore, a recent clinical study further found that
objectively measured poor sleep efficiency was an independent poor prognostic
indicator for survival in advanced breast cancer patients 34. Thus, our findings support
the clinical relevance of regular circadian rhythms, including sleep-wake cycles, in
advanced cancer patients undergoing treatment 32.
Our subgroup analyses furthermore substantiate the hypothesis that excessive toxicity
could hamper the efficacy of circadian-based chronomodulated chemotherapy 8, 30, 32,
33, 35, 36. In this study, we found that the complaint of sleep troubles at the last on-
treatment assessment was correlated with shorter overall survival in patients treated
with chronoFLO4, but not on FOLFOX2. Analysis using sleep problems as a time-
dependent covariate confirmed that the negative prognostic value of sleep complaints
was limited to patients on chronoFLO4. Thus, our findings underscore the hypothesis
that optimal efficacy of circadian-based chronotherapy is associated with optimal
tolerability 32, 33, 37. Indeed, the persistence of robust circadian function during
chemotherapy, a recently documented phenomenon 38, associated with lower
incidence and/or severity of chemotherapy toxicity, has been shown to predict for
better efficacy of chronotherapy 8, 30, 32, 33, 35, 36. Thus, as for severe neutropenia or
clinically meaningful fatigue and/or weight loss, subjective sleep complaints during
treatment might reflect disrupted circadian function, decreasing chronotherapy
effectiveness.
In this study, we screened for subjective sleep complaints using an item from a
validated and widely used HRQoL questionnaire, with translations available in every
suitable language for the study population 24, 39. The EORTC QLQ-C30 evaluates
sleep with a single question, as part of a multidimensional patient-rated questionnaire.
Given the various forms of possible sleep troubles, the use of a single item, although
validated for this assessment, constitutes a limitation of this study. Another
limititation is the compliance rate, which was suboptimal, as only 64% of patients
provided sleep data for the current study.
The strengths of this study include a large sample size, the prospective collection of
data, and a homogeneous population of patients previously untreated for metastatic
disease. Our present findings are in agreement with recent results in women with
advanced breast cancer 34, and provide insight into the relationship between sleep,
circadian rhythms, chemotherapy toxicity, and clinical outcomes in cancer patients.
Disturbed sleep is related to circadian disruption, and both sleep disorders and
circadian disruption have detrimental effects on immunity and metabolic processes 14,
28, 32, 37, 40. The alleviation of sleep complaints through behavioral and/or
pharmacologic interventions could potentially improve circadian function, and jointly
enhance both quality of life and overall survival. Therefore, future research is
warranted in an attempt to improve sleep and circadian function in cancer patients,
using cognitive-behavioral approaches and/or chronobiotic agents 15, 32.
Table 1.
Clinical and demographic features of the whole study population, and separately
according to the presence or not of subjective sleep complaints at baseline.
Variable Total study
population
(N=361)
Sleep complaints
No
(N=159)
Yes
(N=202)
No. (%) No. (%) No. (%)
Age Median
(range)
62.0
(22.3-75.9)
61.1
(34.5-75.5)
62.2
(22.3-75.9)
Randomized
treatment
FOLFOX2 188 (52.1) 82 (51.6) 106 (52.5)
chronoFLO4 173 (47.9) 77 (48.4) 96 (47.5)
Sex Female 140 (38.8) 51 (32.1) 89 (44.1)
Male 221 (61.2) 108 (67.9) 113 (55.9)
Primary tumor Colon 348 (96.4) 155 (97.5) 193 (95.5)
Resected 312 (86.4) 136 (85.5) 176 (87.1)
Prior adjuvant
chemotherapy
Yes 67 (18.6) 31 (19.5) 34 (16.8)
Synchronous
metastases
Yes 268 (74.2) 114 (71.7) 154 (76.2)
Number of metastatic
sites
1 146 (40.4) 69 (43.4) 77 (38.1)
2 133 (36.8) 52 (32.7) 81 (40.1)
> 3 82 (22.7) 38 (23.9) 44 (21.8)
PS (WHO) 0 180 (49.9) 96 (60.4) 84 (41.6)
1 147 (40.7) 52 (32.7) 95 (47.0)
2 34 (9.4) 11 (6.9) 23 (11.4)
Body Mass Index
(Kg/m2)
Normal (18.5-24.9) 181 (50.1) 73 (45.9) 108 (53.5)
Abnormal
(<18.5 or > 25.0)
180 (49.9) 86 (54.1) 94 (46.5)
Baseline Biology Hb < 12 g/dL 144 (39.9) 60 (37.7) 84 (41.6)
WBC > 10*10 9/L 84 (23.3) 31 (19.5) 53 (26.2)
ALP > 300 IU/L 82 (22.7) 34 (21.4) 48 (23.8)
LDH > 2x ULN 127 (35.2) 55 (34.6) 72 (35.6)
Note: PS (WHO)-Performance Status, Hb-Haemoglobin, WBC-white blood count,
ALP-Alkaline Phosphatases, LDH-Lactate Dehydrogenases
Table 2.
Final multivariate proportional Cox regression hazard models for overall survival
with subjective sleep complaints at baseline, on treatment, and as time-dependent
covariate, in the whole study population.
Variable HR (95% CI) P
At baseline
Sleep complaints No 1 0.011
Yes 1.36 (1.07-1.72)
WHO PS 0 1 0.010
1 1.33 (1.03-1.72)
2 1.91 (1.22-2.99)
No. of metastatic
sites
1 1 <0.0001
2 1.52 (1.15-2.00)
≥ 3 3.05 (2.21-4.20)
LDH ≤ 2x ULN 1 0.016
> 2x ULN 1.33 (1.02-1.75)
Unknown 1.69 (1.11-2.57)
On treatment
Sleep complaints No 1 0.234
Yes 1.16 (0.91-1.48)
No. of metastatic
sites
1 1 < 0.0001
2 1.49 (1.12-1.98)
≥ 3 2.73 (1.96-3.82)
LDH ≤ 2x ULN 1 0.010
> 2x ULN 1.45 (1.09-1.93)
Unknown 1.66 (1.09-2.55)
WHO PS (at day 1
of the cycle of last
questionnaire)
0 1 < 0.0001
1 1.62 (1.22-2.15)
2 2.18 (1.37-3.47)
3 9.70 (1.24-76.1)
As time-dependent covariate
Sleep complaints No 1 0.008
Yes 1.37 (1.08-1.72)
WHO PS (at
baseline)
0 1 0.002
1 1.41 (1.09-1.82)
2 2.09 (1.34-3.26)
No. of metastatic
sites
1 1 < 0.0001
2 1.51 (1.15-1.98)
≥ 3 3.01 (2.19-4.14)
LDH ≤ 2x ULN 1 0.013
> 2x ULN 1.40 (1.06-1.84)
Unknown 1.64 (1.08-2.49)
Table 3.
Univariate and multivariate Hazard ratios (95% CI) for overall survival of subjective
sleep complaints at baseline, on treatment, and as time-dependent covariate,
separately in the FOLFOX2 and chronoFLO4 treatment arms.
Subjective
sleep
complaints
(yes)
FOLFOX2 chronoFLO4
Univariate Multivariate Univariate Multivariate
HR P HR p HR p HR p
At
baseline
1.41
(1.04-
1.93)
0.029 1.40
(0.99-
1.97)
0.056 1.40
(1.02-
1.93)
0.040 1.60
(1.11-
2.32)
0.012
On
treatment
1.05
(0.78-
1.43)
0.75 1.20
(0.82-
1.74)
0.35 1.53
(1.11-
2.11)
0.009 1.38
(0.95-
2.01)
0.088
As time-
dependent
covariate
1.10
(0.81-
1.49)
0.54 1.27
(0.90-
1.78)
0.18 1.57
(1.14-
2.17)
0.006 1.74
(1.24-
2.44)
0.001
FIGURE LEGENDS
Figure 1.
Study flow-chart.
Figure 2.
Clinical outcomes according to baseline sleep complaints (red: yes; yellow: no). Left
panel: Kaplan-Meier curves for overall survival. Middle panel: Kaplan-Meier curves
for time to progression. Right panel: objective response rate (complete and partial,
WHO criteria), with 95% confidence interval. HR: hazard ratio. OR: odds ratio.
Results presented for univariate analyses.
Figure 3.
Forrest plot for overall survival, indicating the hazard ratio (and 95% confidence
interval) of an earlier death, obtained with univariate Cox proportional regression
hazard models, according to the presence of subjective sleep complaints either at
baseline (left panel) or as time-dependent covariate (right panel).
Figure 4.
Kaplan-Meier curves for overall survival in patients on FOLFOX2 (left panels) or on
chronoFLO4 (right panels), according to sleep complaints (red: yes; yellow: no) at
baseline (top panels), or at the last assessment while on treatment (bottom panels).
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